16.57

2.35% 0.38

After Hours: 16.77 0.20 +1.21%

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $16.57, with a volume of 325.66K. It is up +2.35% in the last 24 hours and down -11.49% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Previous Close:

$16.19

Open:

$16.265

24h Volume:

325.66K

Relative Volume:

0.49

Market Cap:

$735.37M

Revenue:

$9.00M

Net Income/Loss:

$-80.61M

P/E Ratio:

-7.3868

EPS:

-2.2432

Net Cash Flow:

$-82.35M

1W Performance:

-5.91%

1M Performance:

-11.49%

6M Performance:

+200.73%

1Y Performance:

+343.05%

1-Day Range:

$16.27

$17.46

1-Week Range:

$15.77

$18.65

52-Week Range:

$3.635

$24.00

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-03-26

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	16.57	718.51M	9.00M	-80.61M	-82.35M	-2.2432
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Needham	Buy
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

Apr 14, 2026

BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN

Apr 14, 2026

Apr 13, 2026

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - Bitget

Apr 13, 2026

BioAge CEO's April 16 fireside chat will stream live online - Stock Titan

Apr 13, 2026

Weekly Trades: Is BioAge Labs Inc in accumulation or distribution phaseMarket Activity Report & Free High Return Stock Watch Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN

Apr 11, 2026

Apr 10, 2026

Fund Flows: Can BioAge Labs Inc expand its profit margins2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 10, 2026

The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself — And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells - Baystreet.ca

Apr 10, 2026

Apr 07, 2026

Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore

Apr 07, 2026

What date does BioAge Labs, Inc.'s (BIOA) report EarningsEarnings Calendar & Announcement - Zacks Investment Research

Apr 07, 2026

Apr 05, 2026

Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn

Apr 05, 2026

Apr 03, 2026

BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK

Apr 03, 2026

BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com South Africa

Apr 03, 2026

BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan

Apr 03, 2026

Apr 02, 2026

Risk Hedge: How do insiders feel about BioAge Labs IncWeekly Profit Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn

Apr 02, 2026

BIOA PE Ratio & Valuation, Is BIOA Overvalued - Intellectia AI

Apr 02, 2026

Short Covering: Can BioAge Labs Inc lead its sector in growthWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn

Apr 02, 2026

Apr 01, 2026

Paul Rubin reports three 7,433-share sales (BIOA) in Form 144 - Stock Titan

Apr 01, 2026